Kiyuna Asanori, Ikegami Taro, Uehara Takayuki, Hirakawa Hitoshi, Agena Shinya, Uezato Jin, Kondo Shunsuke, Yamashita Yukashi, Deng Zeyi, Maeda Hiroyuki, Suzuki Mikio, Ganaha Akira
1Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, 903-0215 Japan.
2Department of Otorhinolaryngology, Head and Neck Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Infect Agent Cancer. 2019 Mar 5;14:8. doi: 10.1186/s13027-019-0224-y. eCollection 2019.
Oropharyngeal cancers associated with high-risk type human papillomavirus (HR-HPV) infection have better prognosis than virus negative cancers. Similarly, the HPV status in laryngeal cancer (LC) may be associated with better outcome.
Samples from 88 patients with LC were investigated using the polymerase chain reaction (PCR) and p16 immunohistochemistry for HR-HPV analysis. The cut-off point for p16 overexpression was diffuse (≥75%) tumor expression with at least moderate (+ 2/3) staining intensity.
The 5-year cumulative survival (CS) rate was 80.7% in all patients with LC. According to a combination of HR-HPV DNA status and p16 overexpression, subjects with LC were divided into four groups: HR-HPV DNA-positive/p16 overexpression-positive ( = 5, 5.7%; CS = 100%), HR-HPV DNA-positive/p16 overexpression-negative ( = 11, 12.5%; CS =81.8%), HR-HPV DNA-negative/p16 overexpression-positive ( = 0), and HR-HPV DNA-negative/p16 overexpression-negative ( = 72, 81.8%; CS = 79.5%). HR-HPV DNA-positive/p16-positive cases tended to have integrated HPV infection and high viral load, compared with HR-HPV DNA-positive/p16 overexpression-negative cases.
LC patients with HPV infection and high levels of p16 expression might have an improved survival outcome; however, it is necessary to recruit additional LC cases with HPV infection to determine the definitive characteristics of HPV-mediated LC and estimate survival outcome. These results may contribute to the development of a useful method for selecting patients with a potentially fair response to treatment and ensure laryngeal preservation.
与高危型人乳头瘤病毒（HR-HPV）感染相关的口咽癌比病毒阴性癌症预后更好。同样，喉癌（LC）中的HPV状态可能与更好的预后相关。
对88例LC患者的样本进行聚合酶链反应（PCR）和p16免疫组织化学检测，以分析HR-HPV。p16过表达的临界点为肿瘤弥漫性（≥75%）表达且染色强度至少为中度（+2/3）。
所有LC患者的5年累积生存率（CS）为80.7%。根据HR-HPV DNA状态和p16过表达的组合，LC患者分为四组：HR-HPV DNA阳性/p16过表达阳性（=5例，5.7%；CS=100%），HR-HPV DNA阳性/p16过表达阴性（=11例，12.5%；CS=81.8%），HR-HPV DNA阴性/p16过表达阳性（=0例），以及HR-HPV DNA阴性/p16过表达阴性（=72例，81.8%；CS=79.5%）。与HR-HPV DNA阳性/p16过表达阴性病例相比，HR-HPV DNA阳性/p16阳性病例往往存在整合型HPV感染且病毒载量高。
HPV感染且p16表达水平高的LC患者可能有更好的生存结果；然而，有必要纳入更多HPV感染的LC病例，以确定HPV介导的LC的明确特征并评估生存结果。这些结果可能有助于开发一种有用的方法，用于选择对治疗可能有良好反应的患者并确保保留喉部。
